Starting at 0.25 mg and gradually increasing to 0.5 mg, then 1.0 mg, then 1.7 mg, and finally 2.4 mg gives your GLP-1 receptors time to adjust
A.LuqueG
San Pedro de Atacama was founded in 1450
SGLT2 inhibitors (such as dapagliflozin or empagliflozin), often co-prescribed with GLP-1 agonists for diabetes management, work by increasing glucose excretion in urine, which increases urinary frequency as an expected and common pharmacological effect
Whilst high B12 itself is not typically harmful, it may indicate an underlying condition requiring investigation and management
Education initiatives aimed at promoting understanding of type 2 diabetes and obesity, combined with successful outcomes from GLP-1 therapies, are leading to higher prescription rates